Stocks and Investing
Stocks and Investing
Thu, July 20, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Geoff Meacham Initiated (ABOS) at Strong Buy and Held Target at $14 on, Jul 20th, 2023
Geoff Meacham of B of A Securities, Initiated "Acumen Pharmaceuticals, Inc." (ABOS) at Strong Buy and Held Target at $14 on, Jul 20th, 2023.
Geoff has made no other calls on ABOS in the last 4 months.
There are 3 other peers that have a rating on ABOS. Out of the 3 peers that are also analyzing ABOS, 0 agree with Geoff's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Geoff
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Monday, July 17th, 2023
- Pete Stavropoulos of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $13 on, Monday, July 17th, 2023
- Judah Frommer of "Credit Suisse" Maintained at Buy with Decreased Target to $13 on, Tuesday, March 28th, 2023
Contributing Sources